In Massachusetts, Latest Annual Snapshot Shows a Tale of Two Biopharmas

The job contraction, according to MassBio, reflected pipeline reprioritization by biopharma giants plus contraction by smaller companies, with R&D jobs dropping significantly between Q2 and Q3 of 2025 before starting to bounce back by Q4.

That mid-year drop explained last year's overall 3.9% (2,563-job) decrease in R&D employment statewide, which fell to 62,991 from 65,554 jobs.